Cargando…

TRLS-15. TARGETED THERAPY IN PEDIATRIC CNS TUMORS - A SINGLE INSTITUTION EXPERIENCE

Primary central nervous system malignancy treatment remains a difficult problem despite advancement in techniques. Personalized medicine is evolving in making treatment decisions and particular molecular characteristics allow new targeted therapies to be specific and effective. We retrospectively pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Olsen, Braden, Gonzalez, Keishla, del Riego, Angela Parra, Torres, Marleni, Pabon, Camila, Maher, Ossama, Niazi, Toba, Ragheb, John, Hall, Matthew, Khatib, Ziad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Final Category: Translational Therapeutics/Clinical Trials - TRLS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259902/ http://dx.doi.org/10.1093/neuonc/noad073.318

Ejemplares similares

TRLS-08. EXPERIENCE WITH THE SELECTIVE FIBROBLAST GROWTH FACTOR INHIBITOR ERDAFITINIB IN THREE PEDIATRIC PATIENTS WITH CNS TUMORS
por: Stepien, Natalia, et al.
Publicado: (2023)

TRLS-01. FDA ANALYSIS OF EXPANDED ACCESS USE IN PEDIATRIC PATIENTS WITH CNS TUMORS FROM 2015 TO 2020
por: Duke, Elizabeth, et al.
Publicado: (2023)

TRLS-03. IBRUTINIB DISRUPTS BLOOD-TUMOR BARRIER INTEGRITY TO ENHANCE CNS DRUG DELIVERY AND RODENT GLIOMA MODEL SURVIVAL
por: Lim, Sanghee, et al.
Publicado: (2023)

TRLS-16. RAPID GENERATION OF EPENDYMOMA MOUSE MODELS FOR PRE-CLINICAL STUDIES
por: Ippagunta, Siri, et al.
Publicado: (2023)

TRLS-04. PRECLINICAL VALIDATION OF A NOVEL THERAPEUTIC STRATEGY FOR CHOROID PLEXUS CARCINOMA
por: Martin, Brice, et al.
Publicado: (2023)

TRLS-14. TARGETING REPLICATIVE STRESS IN BRAIN TUMORS BY COMBINING ATR AND PARP INHIBITION
por: Sarvode, Supriya, et al.
Publicado: (2023)

TRLS-02. FEASIBILITY OF EVALUATING ABEMACICLIB NEUROPHARMACOKINETICS OF DIFFUSE MIDLINE GLIOMA USING INTRATUMORAL MICRODIALYSIS
por: Jackson, Sadhana, et al.
Publicado: (2023)

TRLS-09. USE OF A PAN-PEPTIDE CHECKPOINT INHIBITOR IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS
por: Moertel, Christopher, et al.
Publicado: (2023)

TRLS-10. ROVER: A PHASE 1/2 STUDY OF AVAPRITINIB IN PEDIATRIC PATIENTS WITH SOLID TUMORS DEPENDENT ON KIT OR PDGFRA SIGNALING
por: Koschmann, Carl, et al.
Publicado: (2023)

TRLS-13. NOVEL PAN-RAF INHIBITOR BELVARAFENIB AS A PROMISING TARGETED THERAPY FOR BRAF-ALTERED PEDIATRIC LOW-GRADE GLIOMAS
por: Gonzalez, Maxine, et al.
Publicado: (2023)

TRLS-11. A PHASE 1 STUDY OF SAVOLITINIB IN RECURRENT, PROGRESSIVE, OR REFRACTORY MEDULLOBLASTOMA, HIGH-GRADE GLIOMA, DIFFUSE INTRINSIC PONTINE GLIOMA, AND CENTRAL NERVOUS SYSTEM (CNS) TUMORS HARBORING MET ABERRATIONS: A PEDIATRIC BRAIN TUMOR CONSORTIUM TRIAL
por: Salloum, Ralph, et al.
Publicado: (2023)

TRLS-12. INTRAVENTRICULAR B7-H3 CAR T CELLS FOR DIFFUSE INTRINSIC PONTINE GLIOMA: INTERIM ANALYSIS OF BRAINCHILD-03 ARM C
por: Vitanza, Nicholas, et al.
Publicado: (2023)

TRLS-06. A PHASE 1, SAFETY AND DOSE ESCALATION STUDY OF BXQ-350 IN COMBINATION WITH RADIATION IN PEDIATRIC PATIENTS WITH DIFFUSE MIDLINE GLIOMA OR DIFFUSE INTRINSIC PONTINE GLIOMA
por: Dorris, Kathleen, et al.
Publicado: (2023)

TRLS-07. GLOBAL POST-MARKETING SURVEILLANCE DATA FROM PEDIATRIC AND ADULT PATIENTS WITH CENTRAL NERVOUS SYSTEM MALIGNANCIES TREATED WITH TUMOR TREATING FIELDS (TTFIELDS) THERAPY BETWEEN 2011–2022
por: Mrugala, Maciej M, et al.
Publicado: (2023)

TRLS-05. PRELIMINARY RESULTS FROM A PHASE I TRIAL TO EVALUATE INTRAVENTRICULAR DELIVERY OF IL13RΑ2-TARGETING CAR T CELLS AFTER LYMPHODEPLETION IN PEDIATRIC BRAIN TUMORS PATIENTS
por: Davidson, Tom, et al.
Publicado: (2023)

SYST-12 LP-184, A NOVEL ACYLFULVENE-DERIVED TUMOR SITE ACTIVATED SMALL MOLECULE INHIBITS ADULT AND PEDIATRIC CNS TUMOR CELL GROWTH
por: Kulkarni, Aditya, et al.
Publicado: (2023)

NFB-07. Meningiomatosis in an adolescent with TRAF-7 mutation related syndrome
por: Torres, Marleni, et al.
Publicado: (2022)

OTHER-10 EARLY CLINICAL EXPERIENCE OF SRS AND SBRT STEREOTACTIC BODY RADIOTHERAPY FOR CENTRAL NERVOUS SYSTEM (CNS) CASE SERIES AT HCG CANCER CENTRE, NAIROBI.
por: Ahmed, Komen, et al.
Publicado: (2023)

SYST-28 FUNCTIONAL MAPPING REVEALS WIDESPREAD REMODELLING AND A NOVEL TARGETABLE PTP4A2-ROBO1 SIGNALING AXIS AT GLIOBLASTOMA RECURRENCE
por: Chokshi, Chirayu, et al.
Publicado: (2023)

SYST-16 ANXA5 PROMOTES GLIOMA PROGRESSION THROUGH THE FAK/PI3K/AKT PATHWAY
por: Zhang, Xinyuan, et al.
Publicado: (2023)

SYST-25 MICROGLIA-SECRETED LIPID SPECIES DRIVE GLIOMA INVASION
por: Pallares-Moratalla, Carla, et al.
Publicado: (2023)

SYST-32 A NOVEL APPROACH TO TARGET TREG-MEDIATED IMMUNOSUPPRESSION IN GBM
por: Pant, Ayush, et al.
Publicado: (2023)

SYST-13 AAV VECTOR ENCODING FC MODIFIED HER2 ANTIBODIES REDUCES TUMOR BURDEN WITH MINIMIZED PERIPHERAL EXPOSURE IN MODELS OF BREAST CANCER BRAIN METASTASIS
por: Laks, Dan, et al.
Publicado: (2023)

SYST-05 BETA-ADRENERGIC BLOCKADE LICENSES THE USE OF IMMUNOTHERAPY IN PRIMARY AND METASTATIC BRAIN TUMORS
por: Lorrey, Selena, et al.
Publicado: (2023)

SYST-33 GENERATION OF ALLOGENEIC CAR-T CIRCUMVENTS FUNCTIONAL DEFICITS IN PATIENT-DERIVED AUTOLOGOUS PRODUCT FOR GLIOBLASTOMA
por: Shaikh, Muhammad Vaseem, et al.
Publicado: (2023)

SYST-26 INVESTIGATING THE FUNCTIONAL ROLE OF GPNMB IN GLIOBLASTOMA AND THE TUMOR IMMUNE MICROENVIRONMENT AND ITS TARGETED ELIMINATION USING CAR-T CELLS
por: Savage, Neil, et al.
Publicado: (2023)

SYST-14 D2C7 CAR EFFECTIVELY AND SAFELY TREATS EGFRWT AND EGFRVIII-EXPRESSING TUMORS FOLLOWING INTRACRANIAL ADMINISTRATION
por: Wilkinson, Daniel, et al.
Publicado: (2023)

SYST-10 ENHANCING THE EFFICACY OF RADIATION THERAPY BY SURGICALLY TARGETED RADIATION-SENSITIZER LOADED FIBRIN GLUE
por: Nguyen, Jane, et al.
Publicado: (2023)

SYST-22 INTEGRATING GENE DEPENDENCY INTO A PEDIATRIC-FOCUSED CANCER DATA PORTAL FOR TARGETED THERAPY AND BIOMARKER DISCOVERY
por: Sun, Claire, et al.
Publicado: (2023)

SYST-24 PROPOFOL EXERTS ANTI-TUMOR EFFECTS IN GLIOMA AND THE TUMOR MICROENVIRONMENT VIA NON-CODING RNAS AND SECRETED EXOSOMES
por: Penning, Donald, et al.
Publicado: (2023)

SYST-31 PROBIOTIC DELIVERY TO ORTHOTOPIC GLIOBLASTOMA MULTIFORME MODELS AS AN IMMUNOTHERAPY
por: Windemuth, Sophia, et al.
Publicado: (2023)

SYST-03 PHASE 1B STUDY OF AVELUMAB AND WHOLE BRAIN RADIOTHERAPY (WBRT) IN PATIENTS WITH LEPTOMENINGEAL DISEASE (LMD) FROM EPITHELIAL CARCINOMAS: FINAL RESULTS AND MOLECULAR ANALYSES WITH SINGLE CELL RNA SEQUENCING
por: Pina, Yolanda, et al.
Publicado: (2023)

SYST-07 PLASMA MEMBRANE PROFILING REVEALS A TARGETABLE CELL-SURFACE PHENOTYPE OF WNT-MEDULLOBLASTOMA
por: Taylor, Jessica, et al.
Publicado: (2023)

SYST-18 BELZUTIFAN TREATMENT FOR PATIENTS WITH VON HIPPEL-LINDAU DISEASE–ASSOCIATED CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS ENROLLED IN THE PHASE 2 LITESPARK-004 STUDY
por: Narayan, Vivek, et al.
Publicado: (2023)

SYST-08 ROLE OF THE MICROBIOME IN BRAIN TUMORS
por: Omer, Mohammed
Publicado: (2023)

SYST-27 INTERROGATION OF THE TUMOR IMMUNE MICROENVIRONMENT REVEALS DISTINCT IMMUNOSUPPRESSIVE LANDSCAPES IN GLIOBLASTOMA
por: Weng, Linqian, et al.
Publicado: (2023)

SYST-15 GENERATION AND MULTI-DIMENSIONAL PROFILING OF A CHILDHOOD CANCER CELL LINE ATLAS DEFINES NEW THERAPEUTIC OPPORTUNITIES
por: Daniel, Paul, et al.
Publicado: (2023)

SYST-23 CDK1 AS AN INDEPENDENT PROGNOSTIC INDICATOR AND POTENTIAL THERAPEUTIC TARGET IN GLIOMA
por: Wang, Yu, et al.
Publicado: (2023)

SYST-17 GOLD NANOSTARS ENHANCE THE EFFICACY AND SAFETY OF LASER INTERSTITIAL THERAPY FOR THE TREATMENT OF INTRACRANIAL TUMORS
por: Wachsmuth, Lucas, et al.
Publicado: (2023)

SYST-20 TARGETED THERAPY MATCHED TO GENOMIC ALTERATIONS (BRAFV600E, NTRK, FGFR, ROS1, PIK3CA, PTEN) IN PATIENTS WITH RECURRENT IDH WILDTYPE GLIOBLASTOMA: A REAL-LIFE COHORT ANALYSIS FROM VENETO INSTITUTE OF ONCOLOGY, PADUA (ITALY)
por: Padovan, Marta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lj2gu08bk83oupsgakugnbj56h